Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, posted the following on X:
“ASCT is dead! Long live ASCT!
Headline results of updated TRIANGLE study results from Martin Dreyling EMCL network.
Overall survival benefit ~10% for both ibrutinib-containing arms over ASCT alone.
Little benefit to ASCT.
Practice-changing result.”
